HUGO-GT^TM: Revolutionizing Humanized Mouse Models

Q: Are inducible or conditional hACE2 models available for tissue- or time-specific infection studies?

Yes, Cyagen offers inducible and conditional hACE2 mouse models: K18-hACE2-2A-CreERT2 Mice: Combine hACE2 expression with a tamoxifen-inducible Cre recombinase, allowing temporal control over gene expression. This model is ideal for studying the effects of SARS-CoV-2 infection at specific developmental stages or time points. ROSA26-LSL-hACE2 Mice: Enable tissue-specific expression of hACE2 when bred with mice expressing Cre recombinase under tissue-specific promoters, facilitating targeted studies of organ-specific infection and pathology.

Q: How precise is the integration of complete human genes? Can specific human isoforms or regulatory elements be accurately mimicked, and what are the limitations in terms of gene size or complexity?

Our proprietary TurboKnockout-Pro™ technology ensures unparalleled precision in complete human gene integration. This advanced approach allows for the seamless insertion of full-length human genes, accurately mimicking endogenous spatial and temporal expression patterns, thereby preserving natural regulation. This capability is critical for faithfully recapitulating human isoforms and their native regulatory elements, even for genes of significant size or complex genomic architecture, providing highly physiologically relevant models for your research.

Q: What are HUGO-GT's capabilities for high-throughput screening and generating custom models quickly?

HUGO-GT™ is designed for accelerated development and high-throughput use. Our ready-to-use models expedite research. For custom projects, our platform ensures rapid generation of new humanized lines, supporting efficient large-scale screening and efficacy studies with exceptional reproducibility.

Q: Given human gene integration, what are the potential immunological responses in the mouse model to the human gene products, and how does HUGO-GT™ account for or mitigate these?

The core principle of HUGO-GT™ is to integrate complete human genes under their native murine promoters, aiming to achieve human gene expression that mimics natural patterns as closely as possible within the mouse. While the study of human gene products in a murine host inherently involves consideration of immunological responses, our meticulous approach to natural regulation and full-length integration is designed to provide a physiologically relevant system. This strategy focuses on studying the human-specific biology and therapeutic interactions, thereby enabling researchers to focus on human-relevant outcomes for their studies.

Q: How do HUGO-GT™ models address potential immunological responses to human gene products in mice?

HUGO-GT™ integrates human genes under native murine promoters for natural expression. While mouse immunological responses to human products are inherent, our approach focuses on providing physiologically relevant systems to study human-specific biology and therapeutic interactions.

Accelerating Drug Discovery with Precise Genome-Wide Humanization Experience accuracy and reliability in preclinical studies with HUGO-GT™ models, powered by our proprietary TurboKnockout-Pro technology.

Accelerating Development

Ready-to-use models speed up translational research workflows

Natural Regulation

Human gene expression mimics endogenous spatial and temporal patterns

Accurate Gene Expression

Full-length hACE2 knock-in under native murine promoter

Overview

Product

FAQs

Overview

Elevate Your Gene Therapy Research with HUGO-GT™

HUGO-GT™ revolutionizes gene therapy research by seamlessly integrating complete human genes into mouse genomes. Our advanced humanized mouse models deliver precision in disease modeling and enhanced translational relevance. Powered by proprietary TurboKnockout-Pro technology, HUGO-GT™ accelerates model development while ensuring exceptional reproducibility. Partner with the platform trusted by leading research institutions and pharmaceutical companies to advance drug development, therapeutic efficacy studies, and translational research.Explore how HUGO-GT™ is reshaping gene therapy research and discover its transformative impact on ongoing studies.

Explore Ready-to-Use Mouse Models

Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.

You Might Also Be Interested In

MouseAtlas Model Library

Search and access curated genetically engineered mouse strains

Turboknockout^® Gene Editing

Fast-track your research with our efficient gene targeting service.

Ophthalmic CRO Platform

Ocular disease models and IND-ready drug evaluation workflows

Gene Therapy CRO Platform

AI-guided AAV design and full-spectrum preclinical validation

Neuroscience CRO Platform

Validated CNS models with behavioral and molecular efficacy data

Antibody Discovery CRO Platform

Human antibody mice and AI tools for rapid therapeutic validation

Product

Model Selection Made Simple

Access Our Model Library >>

Base Strain

Catalog Number

Catalog Number	Name	Base Strain	Research Application
C001523	B6-hCALCA	C57BL/6JCya	Discovery and screening of migraine drugs and therapies; Evaluation of the efficacy and safety of migraine drugs and therapies; Research on vascular biology and blood pressure regulation; Research on cell proliferation and apoptosis; Research on tumor growth inhibition and inflammation; Research on the generation and differentiation of hematopoietic stem/progenitor cells.
C001790	B6-hTREM1	C57BL/6NCya	TREM1-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of inflammatory diseases such as inflammatory bowel disease (IBD) and rheumatoid arthritis (RA); Research on the pathological mechanisms and therapeutic approaches of cancers such as glioma and hepatocellular carcinoma; Research on the pathological mechanisms and therapeutic approaches of neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD).
C001873	B6-huTFRC/huSNCA(3'UTR)	C57BL/6NCya	Research on neurodegenerative diseases such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA); Development, screening, and preclinical evaluation of TFRC/SNCA-targeted drugs; Research on iron metabolism disorders and tumorigenesis and progression.
I001220	B6-hPCSK9/Apoe KO	C57BL/6Cya	Development, screening, and preclinical evaluation of PCSK9-targeted drugs; Research on metabolic diseases such as hyperlipidemia, stroke, coronary heart disease, familial hypercholesterolemia (FH), and other atherosclerotic cardiovascular diseases (ASCVD).
C001713	B6-hIL2RA	C57BL/6NCya	IL2RA-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of autoimmune diseases such as multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. Tumor immunology and other anti-tumor research.
C001711	B6-hBAFFR (hTNFRSF13C)	C57BL/6NCya	TNFRSF13C-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of immune-mediated disorders such as common variable immunodeficiency (CVID), systemic lupus erythematosus (SLE), and Sjögren's syndrome; Research on the pathological mechanisms and therapeutic approaches of certain B cell malignancies.
C001569	B6-hMECP2*T158M	C57BL/6NCya	B6-hMECP2*T158M mice can serve as a valuable model for studying the mechanisms of RTT and could potentially be used to develop or validate targeted therapies.
C001808	B6-hCCR8	C57BL/6NCya	CCR8-targeted drug screening, development, and evaluation; Research on the pathological mechanisms and therapeutic approaches of allergic disorders (like asthma and atopic dermatitis); Research on the pathological mechanisms and therapeutic approaches of various cancers (e.g., malignant melanoma, hepatocellular carcinoma, cutaneous T-cell lymphomas); Research on the pathological mechanisms and therapeutic approaches of chronic inflammatory conditions such as chronic obstructive pulmonary disease (COPD) and potentially multiple sclerosis (MS); Research on HIV-1 infection.
C001610	B6-hATP7B*H1069Q	C57BL/6NCya	Research on hepatolenticular degeneration (HLD); Preclinical evaluation of ATP7B-targeted drugs.
C001512	B6-hTTR	C57BL/6NCya	The B6-hTTR Mice can be used in research on Transthyretin amyloidosis (ATTR), such as Transthyretin Cardiac Amyloidosis Myocardiopathy (ATTR-CM) and Transthyretin Amyloid Polyneuropathy (ATTR-PN).

Items: 1 to 10 of 319

...

FAQs

Frequently Asked Questions (FAQs)

Are inducible or conditional hACE2 models available for tissue- or time-specific infection studies?

How precise is the integration of complete human genes? Can specific human isoforms or regulatory elements be accurately mimicked, and what are the limitations in terms of gene size or complexity?

What are HUGO-GT's capabilities for high-throughput screening and generating custom models quickly?

Given human gene integration, what are the potential immunological responses in the mouse model to the human gene products, and how does HUGO-GT™ account for or mitigate these?

How do HUGO-GT™ models address potential immunological responses to human gene products in mice?

Citation Database

Molecular Therapy: Methods & Clinical Development, March, 2025

Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing

【Other】

Gut, February, 2025

E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression

【Other】

Cell Death & Disease, February, 2025

Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage

【Other】

Molecular Therapy, February, 2025

Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer

【Other】

Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.

Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:

Yes, I want to receive updates on products, services, and events from Cyagen.

You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.

By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

HUGO-GTTM: Revolutionizing Humanized Mouse Models

HUGO-GT^TM: Revolutionizing Humanized Mouse Models